Eli Lilly has seen tremendous revenue growth and become one of the most highly valued pharmaceutical companies in the world based on its GLP-1/GIP agonist tirzepatide – Mounjaro for type 2 diabetes and Zepbound for obesity – and the company has reinvested considerable cash into its broader research and development pipeline as a result. Lilly’s financial capacity has put it in a position to take several big R&D swings, some of which will read out in 2025.
Lilly CMO David Hyman On The Company’s Drive To Take ‘Ambitious Swings’ In R&D
Phase III Orforglipron Obesity Data Due In 2025
Lilly’s revenue is rising rapidly based on its successes in diabetes and obesity, and the company is reinvesting in big plays in those markets as well as in cancer, lipid-lowering and other indications.
